Dr. Samuel Zachary Goldhaber is a distinguished physician-scientist and internationally recognized authority in cardiovascular medicine and thrombosis research. He serves as Professor of Medicine at Harvard Medical School and holds leadership positions at Brigham and Women's Hospital in Boston, where he is Director of Faculty Promotions in the Division of Cardiovascular Medicine. Dr. Goldhaber directs the Brigham and Women's Hospital Thrombosis Research Group, overseeing a comprehensive program dedicated to advancing the understanding and treatment of blood clotting disorders. His career has been marked by significant institutional leadership, including serving as Interim Chief of the Division of Cardiovascular Medicine and Section Head of Vascular Medicine at Brigham and Women's Hospital.
Dr. Goldhaber's pioneering research has transformed clinical approaches to venous thromboembolism, notably demonstrating that right ventricular dilatation and hypokinesis predict adverse prognosis in acute pulmonary embolism. He served as Principal Investigator for pivotal clinical trials that led to the FDA's approval of systemically administered TPA and subsequently, ultrasound-facilitated, catheter-directed thrombolysis for submassive and massive pulmonary embolism. His work on venous thromboembolism prevention earned him the Certificate of Appreciation from the Surgeon General of the United States, while the American Heart Association recognized his scientific contributions with the Distinguished Scientist Award. These achievements have established new standards of care for millions of patients with blood clotting disorders worldwide.
Beyond his research impact, Dr. Goldhaber founded the North American Thrombosis Forum in 2006, a nonprofit organization dedicated to advancing thrombosis education for healthcare providers, patients, and the public. He actively contributes to global medical initiatives as Principal Investigator for numerous observational and randomized trials studying venous thromboembolism, stroke prevention in atrial fibrillation, and direct oral anticoagulants. His current research interests have expanded to address emerging challenges including weight management and autonomic nervous system dysfunction related to post-COVID conditions. Maintaining an active clinical practice focused on general cardiology, vascular medicine, and complex thrombosis cases, Dr. Goldhaber continues to bridge innovative research with exceptional patient-centered care while mentoring the next generation of cardiovascular specialists.
